LUTATHERA SOLUTION FOR INFUSION 370 MBQML 싱가포르 - 영어 - HSA (Health Sciences Authority)

lutathera solution for infusion 370 mbqml

novartis (singapore) pte ltd - lutetium (177lu) oxodotreotide - injection, solution (radiopharmaceutical) - lutetium (177lu) oxodotreotide 370 mbq/ml

Lutathera 유럽 연합 - 영어 - EMA (European Medicines Agency)

lutathera

advanced accelerator applications - lutetium (177lu) oxodotreotide - neuroendocrine tumors - other therapeutic radiopharmaceuticals - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep‑nets) in adults.

LUTATHERA SOLUTION 캐나다 - 영어 - Health Canada

lutathera solution

novartis pharmaceuticals canada inc - lutetium (177lu) oxodotreotide - solution - 370mbq - lutetium (177lu) oxodotreotide 370mbq - antineoplastic agents

LUTATHERA 370 MBqML SOLUTION FOR INFUSION 이스라엘 - 영어 - Ministry of Health

lutathera 370 mbqml solution for infusion

novartis israel ltd - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

LUTATHERA 370 MBqML SOLUTION FOR INFUSION 이스라엘 - 영어 - Ministry of Health

lutathera 370 mbqml solution for infusion

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

LUTATHERA 370 MBqML SOLUTION FOR INFUSION 이스라엘 - 영어 - Ministry of Health

lutathera 370 mbqml solution for infusion

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

LUNET - SRY 이스라엘 - 영어 - Ministry of Health

lunet - sry

s.r.y. (medical services ) ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 600 mbq/ml - lutetium (177lu) oxodotreotide - for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep-nets) in adults.